Trials / Enrolling By Invitation
Enrolling By InvitationNCT06169397
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- Xentria, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XTMAB-16 | XTMAB-16 infusion |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
- First posted
- 2023-12-13
- Last updated
- 2025-07-09
Locations
11 sites across 4 countries: United States, Czechia, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06169397. Inclusion in this directory is not an endorsement.